Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13175535 | 0.86 | L3MBTL1 (0.71) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL12001998 | 0.86 | L3MBTL1 (0.69) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1754732 | 0.85 | KMT2A (0.71) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL435671 | 0.85 | PDPK1 (0.64) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL28106255 | 0.85 | SMN1; SMN2 (0.48) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6201780 | 0.83 | LMNA (0.65) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL20342100 | 0.82 | GABBR2 (0.50) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2915594 | 0.82 | ALDH1A1 (0.46) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1977280 | 0.82 | ALDH1A1 (0.46) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5918571 | 0.82 | GABBR2 (0.50) | L3MBTL1MAPTSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309742-B2 | Use of the PigD protein for catalyzing 1,4-additions of 2-oxoalkanoates to α, β-unsaturated ketones | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309742-B2 | Use of the PigD protein for catalyzing 1,4-additions of 2-oxoalkanoates to α, β-unsaturated ketones | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2012-11-13 | — | — | US | disclosed |
| EP-1928827-B1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1928827-B1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1928827-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008031034-A2 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | L3MBTL1 1755/4885MAPT 30/4885SMN1; SMN2 9/4885 |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | APP, PSEN2, PSEN1 | L3MBTL1 2424/4885MAPT 6/4885SMN1; SMN2 415/4885 |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | L3MBTL1 1755/4885MAPT 30/4885SMN1; SMN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.